The UAE Heart Failure Treatment Drugs Market, estimated at USD 90.7 Mn in 2025, is expected to exhibit a CAGR of 6.5% and reach USD 140.9 Mn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
The strategies adopted by key market players like acquisitions is expected to drive the UAE heart failure treatment drugs market growth over the forecast period. For instance, on March 14, 2022, Pfizer, Inc., a U.S.-based multinational pharmaceutical and biotechnology corporation, completed the US$ 6.70 billion acquisition of Arena Pharmaceuticals Ltd, a U.S.-based biopharmaceutical company, finalizing a deal that involves multiple cardiovascular properties. This collaboration will help Arena Pharmaceuticals Ltd to accelerate its mission to deliver important medicines to patients by using the capabilities of Pfizer, Inc. This will help Pfizer, Inc. to become a science and innovation-driven biopharmaceutical company.
UAE Heart Failure Treatment Drugs Market - Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems regarding the transportation of drugs from one place to another.
COVID-19 had a negative impact on the UAE heart failure treatment drugs market due to reduced patient visits to hospitals. For instance, according to an article published by the International Journal of Cardiology on September 15, 2022, during the COVID-19 pandemic, reductions in Heart Failure (HF) hospitalizations have been widely reported. The main reasons behind this were reallocation of HF staff to care for patients with COVID-19, disruption of multidisciplinary team, cancellation/postponement of elective procedures, and delays in establishing virtual consultations/telemedicine.
UAE Heart Failure Treatment Drugs Market: Key Developments
Increasing launch of new range of products that can improve the efficacy of heart failure treatment are expected to drive the market growth.
For instance, on February 24, 2022, Boehringer Ingelheim International GmbH, a Germany-based pharmaceutical company, announced the launch of Jardiance (empagliflozin) to reduce the risk of cardiovascular death and hospitalization for heart failure in adults. Jardiance’s safety and effectiveness were evaluated as an adjunct to standard of care therapy in a randomized, double-blind, international trial comparing 2,997 participants who received Jardiance, 10 mg, once daily to 2,991 participants who received the placebo. Of the individuals who received Jardiance for an average of about two years, 14% died from cardiovascular causes or were hospitalized for heart failure, compared to 17% of the participants who received the placebo. This benefit was mostly attributable to fewer patients being hospitalized for heart failure.